| Theme | Current Therapy of IBD | |
|---|---|---|
| Title | Effectiveness of Antibiotic Combination Therapy for Ulcerative Colitis | |
| Publish Date | 2012/01 | |
| Author | Toshifumi Ohkusa | Department of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital |
| Author | Shintaro Tsukinaga | Department of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital |
| Author | Shunichi Odawara | Department of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital |
| Author | Jimi Mitobe | Department of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital |
| Author | Eishu Takahara | Department of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital |
| Author | Kan Uchiyama | Department of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital |
| Author | Hiroshi Arakawa | Department of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital |
| Author | Shigeo Koido | Department of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital |
| [ Summary ] | We previously reported that Fusobacterium varium (F. varium) may be a pathogenic factor in relation to ulcerative colitis (UC). We also reported that antibiotic combination therapy against F. varium is effective for active UC treatment. We assess whether antibiotic combination therapy iseffective for induction and maintenance of remission of UC. Patients received amoxicillin 500 mg tds, tetracycline 500 mg tds and metronidazole 250 mg tdsfor two weeks. We selected these three antibiotics because F. varium was sensitive to some antibiotics. Sulfasalazine, 5-aminosalicylic acid, prednisolone and/or probioticsbeing taken in stable doses for set time periods prior to study inclusion were continued. Symptom assessment and colonoscopic evaluations were performed in a blind manner before enrollment, and at 3 and 12 months after treatment. 1) Twenty chronic, active UC patientswith F. varium infection were enrolled consecutively and were randomly assigned to receive amoxicillin, tetracycline or metronidazole per osfor 2 weeks (treatment group ; n=10), or no antibiotics (control group ; n=10). 2) We enrolled 61 steroid-dependent active UC patients (median age 36, range, 16-73 years, male/female : 41/20) whose relapse had occurred during tapering of prednisolone below 15 mg/day and who were unable to be weaned off steroids without clinical relapse. 3) Patients with active UC were enrolled consecutively, and randomly assigned to receive amoxicillin, tetracycline and metronidazole per os for 2 weeks (treatment group ; n=105) or placebo (control group；n=101). In the above three long-term follow-up studies, twoweek antibiotic combination therapy waseffective and safe in patientswith active ulcerative colitis. |
|